Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

711
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
711
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

856
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
856
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

793
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
793
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

803
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
803
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

435
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
435
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

909
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
909

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Performance of Free-Running Cardiac and Respiratory Motion-Resolved Whole-Heart 5D MRI in Congenital Heart Disease Patients Using a Gadolinium Enhanced Fast-Interrupted Steady-State Sequence.

Journal of magnetic resonance imaging : JMRI·2026
Same author

Wideband black- and bright-blood late gadolinium enhancement imaging in patients with implantable cardiac devices at 1.5 T for improved visualization and localization of myocardial injury.

European heart journal. Imaging methods and practice·2026
Same author

Outcomes of Patients With High-Risk Plaques Treated With a Bioresorbable Magnesium Scaffold: Insights From the BIOMAG-I Study.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2026
Same author

Polymer-free sirolimus-based submicron carrier-eluting stent: present and future perspective.

Expert review of medical devices·2026
Same author

Coronary artery Ectatic/Aneurysmatic disease: From pathophysiology to management.

Progress in cardiovascular diseases·2026
Same author

Multiparametric Cardiac Magnetic Resonance Characterization of the Noninfarcted Myocardium: Definition, Assessment, and Clinical Significance.

JACC. Cardiovascular imaging·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

[Erythema multiforme : target deciphering].

Revue medicale suisse·2026
See all related articles

Related Experiment Video

Updated: Apr 15, 2026

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

12.3K

[Cardiology update in 2014].

Juan F Iglesias, Pierre Monney, Patrizio Pascale

    Revue Medicale Suisse
    |March 25, 2015
    PubMed
    Summary
    This summary is machine-generated.

    Key 2014 cardiology advances include new treatments for acute myocardial infarction, optimal dual antiplatelet therapy duration, and novel heart failure medications. Technological breakthroughs in implantable defibrillators and updated European Society of Cardiology guidelines are also highlighted.

    More Related Videos

    Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
    10:17

    Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

    Published on: April 11, 2025

    2.3K
    Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
    13:07

    Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression

    Published on: January 15, 2022

    4.7K

    Related Experiment Videos

    Last Updated: Apr 15, 2026

    Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
    14:24

    Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

    Published on: January 21, 2018

    12.3K
    Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
    10:17

    Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

    Published on: April 11, 2025

    2.3K
    Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
    13:07

    Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression

    Published on: January 15, 2022

    4.7K

    Area of Science:

    • Cardiology
    • Cardiovascular Diseases
    • Medical Technology

    Context:

    • Significant clinical trials and therapeutic advancements were presented in 2014.
    • Published evidence impacts acute myocardial infarction management and dual antiplatelet therapy duration post-stenting.
    • Emerging therapeutic agents show promise for heart failure with reduced ejection fraction.

    Purpose:

    • To review the most important studies and advancements in cardiology from 2014.
    • To cover key developments in interventional cardiology, rhythmology, heart failure, and cardiac imaging.
    • To provide an overview of critical updates for cardiovascular disease management.

    Summary:

    • New evidence guides acute myocardial infarction treatment and dual antiplatelet therapy duration after coronary stenting.
    • Novel therapeutic agents offer hope for heart failure patients with reduced ejection fraction.
    • Technological innovations include new subcutaneous and MRI-compatible implantable defibrillators.
    • Updated European Society of Cardiology guidelines provide comprehensive cardiovascular disease management recommendations.

    Impact:

    • These advancements offer improved therapeutic strategies for cardiovascular conditions.
    • Technological breakthroughs enhance patient care and treatment options.
    • Updated guidelines ensure evidence-based practice in cardiology.
    • The review provides a concise summary of critical 2014 cardiology literature for clinicians and researchers.